BOULDER, Colo. (AP) _ Clovis Oncology Inc. (CLVS) on Wednesday reported a loss of $70.7 million in its fourth quarter.
On a per-share basis, the Boulder, Colorado-based company said it had a loss of $1.83.
The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of $1.65 per share.
The biopharmaceutical company posted revenue of $78,000 in the period.
For the year, the company reported that its loss widened to $349.1 million, or $9.07 per share. Revenue was reported as $78,000.
Clovis shares have increased 38 percent since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $61.19, more than tripling in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLVS at https://www.zacks.com/ap/CLVS
Keywords: Clovis Oncology, Earnings Report